SwaminathanPadmanabhan(Padmanabhan)IyerMD

PubMed

• Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?
  Penny Fang, Sonal S Noticewala, Susan Y Wu, Jillian R Gunther, Ethan B Ludmir
  Advances in Radiation Oncology. 2024-12-01
• Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBAL...
  Swaminathan P Iyer, R Alejandro Sica, P Joy Ho, Anca Prica, Jasmine Zain
  The Lancet. Oncology. 2024-11-28
• Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.
  Rishika Prasad, Abdur Rehman, Lubna Rehman, Faezeh Darbaniyan, Viktoria Blumenberg
  Blood. 2024-10-23

Journal Articles

• A unique aptamer-drug conjugate for targeted therapy of multiple myeloma  
  Wen J, Tao W, Hao S, Iyer SP, Zu Y., Leukemia, 8/5/2015
• A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple...  
  Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC, Br J of Haematol, 8/1/2014
• BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD  
  Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer SP, Bradner JE, Bhalla KN, Mol Cancer Ther, 7/1/2014
• Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses  
  Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J..., J Hematol Oncol., 1/23/2014
• Phase I Study of the Investigational Aurora A Kinase Inhibitor MLN8237 (alisertib) in Patients with Relapsed or Refractory Multiple Myeloma, Non-Hodgkin's Lymphoma and...  
  Kelly KR, Shea TC, Goy A, Berdeja JG, Reeder CB, McDonagh KT, Zhou X, Danaee H, Liu H, Ecsedy JA, Niu H, Benaim E, Padmanabhan Iyer S, Invest New Drugs, 12/1/2013
• A phase I trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma  
  Benson DM Jr, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagganath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri MA, Farag SS, Blood, 11/1/2012
•  
  Bansal H, Seifert T, Bachier C, Rao M, Tomlinson G, Iyer SP, Bansal S, J Biol Chem, 9/1/2012
• Results From a Pivotal, Open-Label, Phase 2 Study of Romidepsin in Progressive or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy  
  Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, C..., J Clin Oncol, 2/1/2012
• Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study  
  Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Osterborg A for the Hx-CD20-406 Study Investigators, Blood, 11/1/2011
• A Cancer Survivorship Study of Perceptions Among Leukemia Patients in the Acute, Extended, and Permanent Survival Phases  
  Pandya DM, Patel S, Ketchum NS, Pollock BH, Padmanabhan S, Clin Lymphoma Myeloma Leuk, 6/1/2011
• Heat shock protein 90 regulates the expression of Wilms' tumor 1 protein in myeloid leukemias  
  Bansal H, Bansal S, Rao M, Foley KP, Sang J, Proia DA, Blackman RK, Ying W, Barsoum J, Baer MR, Kelly K, Swords R, Tomlinson GE, Battiwalla M, Giles FJ, Lee KP, Padman..., Blood, 11/1/2010
• Phase II Trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom’s Macroglobulinemia  
  Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Poon T, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, ..., Am J Hematol, 6/4/2010
• Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors  
  Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ, Target Oncol, 4/1/2009
• Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib  
  Swords R, Mahalingam D, Padmanabhan S, Carew J, Giles F, Drug Design, Development and Therapy, 1/1/2009
• Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide, and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed...  
  Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy PL Jr, Hahn T, Bone Marrow Transplant, 4/1/2008
• High prevalence of early onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy  
  Yao S, McCarthy PL, Dunford LM, Roy DM, Brown K, Paplham P, Syta M, Lamonica D, Smiley S, Battiwalla M, Padmanabhan S, Hahn T, Bone Marrow Transplant, 2/1/2008
• HLA-identical sibling stem cell transplantation in first remission AML  
  Ailawadhi S, Padmanabhan S, Blood, 12/1/2007
• Two cases of hepatic zygomycosis in allogeneic stem cell transplant recipients and review of literature  
  Padmanabhan S, Battiwalla M, Hahn T, Ball D, Paplham P, Brown K, Segal BH, McCarthy P Jr, Almyroudis NG, Transpl Infect Dis, 6/1/2007
• Herpes simplex infections in Solid and Bone marrow transplantations, A Review  
  Varadarajan P and Padmanabhan S, Infectious Disease Practice, 5/1/2007
• Long Term Stability of a Patient-Convenient One mg/mL Suspension of Tacrolimus for Accurate GVHD Prophylaxis Dosing and Maintenance of Stable Therapeutic Levels  
  Elefante, J Muindi, S. Abel, P. Paplham, K. Brown, T. Hahn, S. Padmanabhan, M. Battiwalla, P L. McCarthy Jr, Bone Marrow Transplant, 4/1/2006
• Human Leukocyte Antigen (HLA) DR15 is Associated With Reduced Incidence Of Acute GVHD in HLA-matched Allogeneic Transplants But Does Not Impact Chronic GVHD Incidence  
  Battiwalla M, Hahn T, Radovic M, Roy H, Wahab A, Duman E, Bajwa R, Padmanabhan S, Becker J, Barrett AJ, McCarthy Jr PL, Blood, 1/1/2006
• Simultaneous presentation of acute myeloid leukemia (FAB-M5a) and mantle cell lymphoma: a case report and review of literature  
  Pawarode A, Baer MR, Padmanabhan S, Wallace PR, Barcos M, Sait S, Wetzler M, Battiwalla M, Leuk Lymphoma, 12/1/2005
• Protein Kinase C BetaII Plays an Essential Role in Dendritic Cell Differentiation and autoregulates its own expression  
  Cejas PJ, Carlson LM, Zhang J, Padmanabhan S , Kolonias D, Lindner I, Haley S, Boise LH and Lee KP, J. Biol. Chem, 8/1/2005
• CD8 T cell and Clinical Response to Allogeneic Whole Cell Immunization of patients with Advanced Non Small Cell Lung Carcinoma  
  Raez LE, Cassileth PA, Schlesselman JL, Padmanabhan S, Fisher EZ, Baldie PA, Sridhar KS and Podack ER, Cancer Gene Therapy, 1/1/2003
• Join now to see all

Books/Book Chapters

• Breast Cancer- A Practical Guide 
  Iyer SP et al.Editors: Silva, Orlando E. & Zurrida, Stefano.Elsevier Saunders PublishersEdition 3rd,2005

Abstracts/Posters

• Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell LymphomaRadiation Therapy Can be ...
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
• Novel CD4+CD8+ Umbilical Cord Blood Regulatory T Cells
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Re...
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Cord Blood Regulatory T Cells Prevent Mutiple Myeloma Progression By Suppressing Inflammation
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical and Radiological Correlates of Neurotoxicity after Standard of Care Axicabtagene Ciloleucel in Patients with Relapsed/Refractory Large B-Cell Lymphoma
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase I Clinical Trial of CK0801 (cord blood regulatory T cells) in Patients with Bone Marrow Failure Syndrome (BMF) Including Aplastic Anemia, Myelodysplasia and Myel...
  Swami P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantat...
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (_65 years) Patients with Mantle Cell Lymphoma (MCL) _ Results from a...
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Single Injection of Cord Blood Regulatory T Cells Can Delay the Manifestations of Systemic Lupus Erythematosus
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Co...
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• MYC Expression in Systemic Anaplastic Large Cell Lymphoma: Clinicopathologic and Prognostic Features of 70 Patients
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation
  Swaminathan P. Iyer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Combined Therapy With BRD4 Antagonist and FLT3 Inhibitor Exerts Synergistic Activity Against Cultured and Primary AML Blast Progenitors Expressing FLT-ITD
  Melissa Rodriguez, M.D., Ph.D, Warren Fiskus, Ph.D, Sunil Sharma, MD, Jun Qi, PhD, John A Valenta, M.S., Leasha J Schaub, M.S, Bhavin Shah, Santhana Devaraj, Ph.D, Swa..., Molecular Pharmacology, Drug Resistance, 12/9/2013
• BRD4 Antagonist and Histone Deacetylase Inhibitor: A Novel Synergistic Combination Against Human Acute Myeloid Leukemia (AML) Cells
  Warren Fiskus, Ph.D, Sunil Sharma, MD, Jun Qi, PhD, John A Valenta, M.S., Leasha J Schaub, M.S., Bhavin Shah, Karissa Peth, Laxmi U.M.R. Jakkula, PhD, Melissa Rodrigue..., Molecular Pharmacology, Drug Resistance: Molecular Mechanisms of Drug Resistance and Novel Targets in Acute Myeloid Leukemia, 12/9/2013
• A Phase I Study of An Oral Hedgehog Pathway Antagonist, BMS-833923, in Patients with Relapsed or Refractory Multiple Myeloma
  Carol A. Huff, MD, Swaminathan Padmanabhan, MD, Kevin R. Kelly, MD, George Somlo, MD, Luis Camacho, MD, MPH, Jeffrey Zonder, MD, Bruce Fischer, MD, Lixin Lang, Steven ..., Myeloma - Therapy, excluding Transplantation, 12/12/2011
• Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma
  Bertrand Coiffier, MD, Barbara Pro, MD, H. Miles Prince, MBBS, FRACP, FRCPA, MD, Francine M. Foss, MD, Lubomir Sokol, MD, PhD, Matthew Greenwood, MD, FRCPA, FRACP, Dol..., Lymphoma - Chemotherapy, excluding Pre-Clinical Models: Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma, 12/12/2011
• The Investigational Multi-Targeted Kinase Inhibitor TAK-901 Antagonizes Acute Myeloid Leukemia Pathogenesis: Results of Preclinical Studies
  Patrick Griffin, MD, Steffan T Nawrocki, PhD, Takashi Satou, PhD, Claudia M Espitia, MS, Kevin R. Kelly, MD, Maki Hasegawa, Swaminathan Padmanabhan, MBBS, MD, Angela R..., Acute Myeloid Leukemia - Therapy, excluding Transplantation: Novel Strategies and Preclinical Studies, 12/12/2011
• A Phase I study of BHQ880, a novel osteoblast activating, anti-DKKi human Mab in relapsed and refractory multiple myleloma patients treated with zolendronic acid and a...
  S Padmanabhan, J Beck ,A Stewart ,J Shah ,K Kelly ,K Anderson ,S Bilic ,LM Chiang ,A Dzik-Jurasz ,R Isaacs ,M Li ,P Savage ,M Song ,N Munshi, European Hematology Association, 1/1/2011
• Final Analysis From the International Trial of Single-Agent Ofatumumab in Patients With Fludarabine-Refractory Chronic Lymphocytic Leukemia
  William G. Wierda, Thomas J. Kipps, Jiri Mayer, Tadeusz Robak, Martin J.S. Dyer, Richard Furman, Peter Hillmen, Stephan Stilgenbauer, Andrzej Hellmann, Cathy Williams,..., Therapy, excluding Transplantation: Relapsed/Refractory Disease and Therapeutic Problems, 12/7/2010
• Phase II Study of the Cyclin-Dependent Kinase (CDK) Inhibitor Dinaciclib (SCH 727965) in Patients with Advanced Acute Leukemias
  Ivana Gojo, M.D, Alison Walker, MD, Maureen Cooper, MD, Eric J. Feldman, MD, Swaminathan Padmanabhan, MD, Maria R. Baer, MD, Jennifer Poon, PharmD, Karen Small, BSN, D..., Acute Myeloid Leukemia - Therapy, excluding Transplantation, 12/6/2010
• Phase I study of an Investigational Aurora A Kinase Inhibitor MLN8237 in Patients with Advanced Hematologic Malignancies
  Swaminathan Padmanabhan, Thomas C. Shea, Julie M Vose, Craig B. Reeder, Jesus G. Berdeja, Kevin T. McDonagh, André Goy,Kevin Kelly, Xiaofei Zhou, Hua Liu, Howard Fing..., Lymphoma - Chemotherapy, excluding Pre-Clinical Models, 12/5/2010
• A Pilot Study of the Combination of Nilotinib and Hyper-CVAD for Philadelphia Chromosome Positive Acute Lymphocytic Leukemia and Lymphoid Blast Crisis Chronic Myelogen...
  Edgar Castillo MD, Raed Al-Rajabi MD, Devesh Pandya MD, Prakash Varadarajan MD, and Swaminathan Padmanabhan MBBS, MD, Acute Lymphoblastic Leukemia - Therapy, excluding Transplantation, 12/5/2010
• Join now to see all

Lectures

• Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myel... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Plenary Session-Chronic Lymphocytic Leukemia 
  2/14/2014
• Non-Hodgkin’s Lymphoma- western Database 
  11/22/2013
• Plenary Session- Emerging therapies for Myelofibrosis 
  2/22/2013
• State of the Art Lecture: Treatment Breakthroughs for Relapsed CML 
  9/1/2012
• Should Steroids still be the First Choice for Newly Diagnosed ITP? 
  2/23/2012
• Emerging therapies for TKI refractory/TKI resistant bcr-abl mutations 
  9/2/2011
• Stressing the Importance of Heat Shock Protein90 (HSP90) in Leukemia 
  11/1/2010
• Treatment of MDS in the Era of Novel Agents 
  2/1/2010
• What is new in the treatment of Multiple myeloma 
  10/1/2009
• Opportunities for Clinical Studies in Hematological Malignancies 
  1/1/2009
• Clinical perspectives of flow cytometry in hematological malignancies 
  12/17/2007
• An Overview of Drug Development in Myelodysplastic syndromes 
  11/28/2007
• Acute Leukemia: New Treatments & Promises 
  11/3/2007
• Making Sense of Myelodysplastic Syndromes: From Diagnosis to Treatment 
  10/9/2007
• Evolution in treatment for Multiple Myeloma: Do emerging therapies offer an advantage? 
  9/13/2006
• Advances in Bone Marrow Transplantation: an update for physicians 
  4/24/2006
• Evolving paradigms of managing chronic lymphocytic leukemia-Have we arrived at a cure 
  11/29/2005
• Role of Methyl-Transferase Inhibitors in Hematologic Malignancies 
  11/11/2005
• Current Modalities of management in Chronic Lymphocytic Leukemia 
  10/1/2005
• Clinical Guidelines for Blood & Marrow Transplantation: New Indications for Treatment and Long-Term Assessment-Who are the ideal patients with Lymphoma and Myeloma for... 
  7/1/2005
• Updates on Advances for Treatment of Hematologic Disorders-Review in Chronic Lymphocytic Leukemia 
  1/1/2005
• Join now to see all